JP2023099143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023099143A5 JP2023099143A5 JP2023075372A JP2023075372A JP2023099143A5 JP 2023099143 A5 JP2023099143 A5 JP 2023099143A5 JP 2023075372 A JP2023075372 A JP 2023075372A JP 2023075372 A JP2023075372 A JP 2023075372A JP 2023099143 A5 JP2023099143 A5 JP 2023099143A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- product
- immunoglobulin product
- treatment
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 24
- 102000018358 immunoglobulin Human genes 0.000 claims 24
- 239000000047 product Substances 0.000 claims 20
- 238000000034 method Methods 0.000 claims 18
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 4
- 229940068196 placebo Drugs 0.000 claims 4
- 239000000902 placebo Substances 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 239000012263 liquid product Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488219P | 2017-04-21 | 2017-04-21 | |
| US62/488,219 | 2017-04-21 | ||
| EP17177134 | 2017-06-21 | ||
| EP17177134.8 | 2017-06-21 | ||
| US201762571812P | 2017-10-13 | 2017-10-13 | |
| US62/571,812 | 2017-10-13 | ||
| JP2019556864A JP7275044B2 (ja) | 2017-04-21 | 2018-04-20 | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556864A Division JP7275044B2 (ja) | 2017-04-21 | 2018-04-20 | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023099143A JP2023099143A (ja) | 2023-07-11 |
| JP2023099143A5 true JP2023099143A5 (enExample) | 2024-01-23 |
| JP7621411B2 JP7621411B2 (ja) | 2025-01-24 |
Family
ID=62063037
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556864A Active JP7275044B2 (ja) | 2017-04-21 | 2018-04-20 | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 |
| JP2023075372A Active JP7621411B2 (ja) | 2017-04-21 | 2023-05-01 | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556864A Active JP7275044B2 (ja) | 2017-04-21 | 2018-04-20 | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200055922A1 (enExample) |
| EP (1) | EP3612221A1 (enExample) |
| JP (2) | JP7275044B2 (enExample) |
| CN (1) | CN110831627A (enExample) |
| AU (2) | AU2018253931A1 (enExample) |
| CA (1) | CA3060169A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| HUE028832T2 (en) * | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation |
| CN103080129A (zh) * | 2010-04-08 | 2013-05-01 | 巴塞尔大学医院 | 用于治疗和预防免疫重建炎症综合征（iris）的血浆衍生的免疫球蛋白 |
| AU2010202125B1 (en) * | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| FR2962650B1 (fr) * | 2010-07-19 | 2013-04-05 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines concentrees |
| AU2019274649B2 (en) * | 2018-05-23 | 2025-10-09 | Csl Behring Ag | Treatment of CIDP |
-
2018
- 2018-04-20 EP EP18720203.1A patent/EP3612221A1/en active Pending
- 2018-04-20 AU AU2018253931A patent/AU2018253931A1/en not_active Abandoned
- 2018-04-20 CA CA3060169A patent/CA3060169A1/en active Pending
- 2018-04-20 JP JP2019556864A patent/JP7275044B2/ja active Active
- 2018-04-20 US US16/606,605 patent/US20200055922A1/en active Pending
- 2018-04-20 CN CN201880025896.5A patent/CN110831627A/zh active Pending
-
2023
- 2023-05-01 JP JP2023075372A patent/JP7621411B2/ja active Active
-
2025
- 2025-04-02 AU AU2025202358A patent/AU2025202358A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514132A5 (enExample) | ||
| EP1237559B1 (en) | Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran | |
| JP2023535744A5 (enExample) | ||
| EP1397139A1 (en) | Pharmaceutical combinations | |
| JP7796663B2 (ja) | 過炎症性症候群の処置 | |
| JP2002528502A5 (enExample) | ||
| EP1503748B1 (en) | 2,2'-Dithio-bis(ethanesulfonate) for use in inhibiting paclitaxel-induced abnormal thermoesthesia | |
| JP2005514414A5 (enExample) | ||
| JP2934023B2 (ja) | コルチコステロイド治療組成物 | |
| JP2023545084A5 (enExample) | ||
| JP2021520396A5 (enExample) | ||
| EP2604264B1 (en) | Pharmaceutical composition for treating viral diseases | |
| JP2023099143A5 (enExample) | ||
| JPWO1999018993A1 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| JP2025060703A5 (enExample) | ||
| Hejna et al. | Local use of GM-CSF for severe mucositis | |
| CN101068564A (zh) | 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物 | |
| EA009935B1 (ru) | Новая синергетическая комбинация, включающая рофлумиласт и формотерол | |
| WO2024124152A1 (en) | Rrx-001 for the treatment of a hemoglobinopathy | |
| JP2025511402A5 (enExample) | ||
| JP2025511401A5 (enExample) | ||
| JP2020517636A5 (enExample) | ||
| US7226766B2 (en) | S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide | |
| WO2020207344A1 (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| IL313589A (en) | The compositions containing voriconazole inhalation powder and methods for their production and use |